Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that with ageing population, its prevalence would grow significantly.
One of the major drivers of the Parkinson’s drugs market in the Europe is the rising uptake of key current brands along with the launch of three new therapies which would help sustain the Parkinson’s disease market through 2022. However, growing competition from generics would continue to restrain the market in the future. Consequently, owing to competitive forces, the total sales of therapies used to treat the disease would remain relatively flat over the next decade.
“Europe Parkinson’s Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Parkinson’s disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the European Parkinson’s Disease drug market based upon development process.
Following parameters for each drug profile in development phase are covered in “Europe Parkinson’s Disease Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 12
- Clinical: 26
- Phase-I: 14
- Phase-I/II: 2
- Phase-II: 6
- Phase-II/III: 1
- Phase-III: 3
- Preregistration: 1
- Marketed: 18
2. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: RESEARCH
2.1 Overview
2.2 Parkinson’s Disease Drug Profile in Clinical Phase
3. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PRECLINICAL
3.1 Overview
3.2 Parkinson’s Disease Drug Profile in Clinical Phase
4. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: CLINICAL
4.1 Overview
4.2 Parkinson’s Disease Drug Profile in Clinical Phase
5. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PHASE-I
5.1 Overview
5.2 Parkinson’s Disease Drug Profile in Clinical Phase
6. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PHASE-I/II
6.1 Overview
6.2 Parkinson’s Disease Drug Profile in Clinical Phase
7. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PHASE-II
7.1 Overview
7.2 Parkinson’s Disease Drug Profile in Clinical Phase
8. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PHASE-II/III
8.1 Overview
8.2 Parkinson’s Disease Drug Profile in Clinical Phase
9. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PHASE-III
9.1 Overview
9.2 Parkinson’s Disease Drug Profile in Clinical Phase
10. PARKINSON’S DISEASE CLINICAL DEVELOPMENT PHASE: PREREGISTRATION
10.1 Overview
10.2 Parkinson’s Disease Drug Profile in Clinical Phase
11. MARKETED
11.1 Overview
11.2 Marketed Parkinson’s Disease Drug
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
Alternate Names
Originator & Owner
Collaborator
Technology Provider
Licensee
Highest Development Phase
Indications
Class
Mechanism of Action
ATC code
Designated Brand Name & Orphan Designation
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that with ageing population, its prevalence would grow significantly. The society pays a significant amount towards treating this disease in the region. It is estimated that the total annual cost to the nation exceeds xx billion.
One of the major drivers of the Parkinson’s drugs market in the Europe is the rising uptake of key current brands along with the launch of three new therapies which would help sustain the Parkinson’s disease market through 2022. However, growing competition from generics would continue to restrain the market in the future. Consequently, owing to competitive forces, the total sales of therapies used to treat the disease would remain relatively flat over the next decade.
Among the classes of drugs in the European region, it is expected that dopamine agonists would remain the most popular and would maintain the highest share in the market at close to 30% till 2020. The market for Parkinson’s drugs is currently entering a transition away from the established drugs, and towards new mechanisms of action. There are significant economic consequences of Parkinson’s disease across the European reigon. The annual total cost of the disease to the society is estimated to be €xx billion, which is most likely to increase with the growing number of peole being diagnosed with the disease. With the rising severity of the disease in Europe, it is expected that the annual cost of Parkinson’s per person would also increase. For example, in Germany, the cost of Parkinson’s increased from €xx (for Hoehn and Yahr stages I–2) to €xx (for Hoehn and Yahr stages 2–5 in 2010. Similarly, in UK, the annual cost of Parkinson’s per person in the Hoehn and Yahr stages 3–5 was approximately €xx in 2011.
The costs of Parkinson’s disease are divided into direct costs, which include consultations, hospital admissions, tests and investigations and indirect costs, including early retirement, reduced working hours for carers and institutionalization. Additionally, the healthcare bills for people affected by Parkinson’s disease cost €xx more than those for people without the disease. The additional cost is mainly attributed to longer duration of admission in the hospital, more days in long-term care (such as nursing homes) and increased numbers of prescriptions.
There are major obstacles which the pharma companies need to address before strengthening their positions in the market. Cost in terms of both direct and indirect costs which include consultations, medication and reduced working hours and institutionalization, respectively cause significant concern for the companies. A huge investment is required in order to cover these expenditure heads.
Additionally, medication is another major challenge. Though medication is currently thought to be the cornerstone of management of Parkinson’s disease, challenges remain in rendering the appropriate treatment for the right person across Europe. Also, only medicines would not suffice the process of enhancement and improvement a person’s life with Parkinson’s. there is a huge demand for other therapies also such as physio, speech and language, and occupational. A proper combination of all these components ensures that the patient is receiving a holistic treatment. Inspite of the challenges in Europe Parkinson’s disease market, there are significant opportunities.
These relate to improving the treatment and care offered to people with Parkinson’s. There is adequate evidence that early and appropriate pharmacological intervention has helped the stakeholders to reduce the economic burden to both the individual and society and also helped people who are living with the disease to remain in the workplace for longer, thus in turn encouraging them to contribute to society. One of the major opportunities lies in the unique “European Parkinson’s Disease Standards of Care Consensus Statement”, which when adhered to can create potential returns for both the drug makers and the society at large. This is the first ever document which supports and encourages the drive for equality and optimization of Parkinson’s treatment at both a European and a national level. The Consensus combines the proof of the economic and emotional costs of the disease across Europe, along with the specialized knowledge of a team of experts in this field who are neurologists, geriatricians and members of the various multidisciplinary teams as well as people with Parkinson’s and their carers.
There is a significant demand prevailing in the parkinson’s disease market, which implies that the research activity for developing new drugs would continue to take centre focus in the future. It is most likely that by the end of the decade, many therapies for treating parkinson’s disease would be generalized and this would lead to a fragmented market with no leader. A huge number of similarly prices drugs would compete for the same patient share. Thus, the pharma companies would have to develop novel therapies and drugs which would be capable of clearly differentiating themselves from other therapies in order to gain a competitive edge in this otherwise mature market.
